BSX catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
Windows longer than 90 days are part of TrialScanner, so this list covers the next 90 days.
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 2027Sponsor estimate | NCT07187115A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial...Boston Scientific Corporation · Atrial Fibrillation (AF) | BSXLead | No phase registered | Active, not recruiting | Locked | Locked | Locked |
| Jan 31, 2027Sponsor estimate | NCT05303467A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBMBoston Scientific Corporation · Glioblastoma Multiforme | BSXLead | Phase 1 | Recruiting | Locked | Locked | Locked |
- Primary completion Jan 2027Sponsor estimateNo phase registeredNCT07187115A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial...Boston Scientific Corporation · Atrial Fibrillation (AF)Active, not recruitingBSXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2027Sponsor estimatePhase 1NCT05303467A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBMBoston Scientific Corporation · Glioblastoma MultiformeRecruitingBSXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 15, 2027Sponsor estimate | NCT06510556Feasibility Study of the FARAFLEX Mapping and PFA SystemBoston Scientific Corporation · Atrial Fibrillation | BSXLead | No phase registered | Recruiting | Locked | Locked | Locked |
| Feb 15, 2027Sponsor estimate | NCT06656884FARAPULSE Workflow Assessment RegistryBoston Scientific Corporation · Atrial Fibrillation (AF) | BSXLead | No phase registered | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Feb 15, 2027Sponsor estimateNo phase registeredNCT06510556Feasibility Study of the FARAFLEX Mapping and PFA SystemBoston Scientific Corporation · Atrial FibrillationRecruitingBSXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 15, 2027Sponsor estimateNo phase registeredNCT06656884FARAPULSE Workflow Assessment RegistryBoston Scientific Corporation · Atrial Fibrillation (AF)Active, not recruitingBSXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 4 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.